Viewing Study NCT07151560


Ignite Creation Date: 2025-12-25 @ 2:04 AM
Ignite Modification Date: 2025-12-26 @ 12:29 AM
Study NCT ID: NCT07151560
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-09-03
First Post: 2025-08-25
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
Sponsor: Renmin Hospital of Wuhan University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module